SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like Effective Immediately: Bristol-Myers Squibb Exec to Take the Reins at Kleo June 8, 2017 ImmunoGen Stock Climbs on Positive Ovarian Cancer Data March 25, 2018 Champions Oncology Surges After Inking R&D Deal With This Drug Giant August 20, 2017